International Diabetes Federation. IDF Diabetes Atlas. Fifthwww.idf.org/diabetesatlas/5e/the-global-burden. 2012April.
2.
American Diabetes Association. Diabetes statistics. www.diabetes.org/diabetes-basics/diabetes-statistics/?loc=DropDownDB-stats. 2012April.
3.
HuFB, StampferMJ, SolomonCG, LiuS, WilletWC, SpeizerFE, NathanDM, MansonJE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med, 2001; 161:1717–1723.
4.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 1993; 329:977–986.
5.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352:854–865Erratum in Lancet 1998;352:1558.
6.
HomeP. Cardiovascular disease, oral agent glucose-lowering therapies in the management of type 2 diabetes. Diabetes Technol Ther, 2012; 14,Suppl 1:S-33–S-42.
7.
StrattonIM, AdlerAI, NeilHA, MatthewsDR, ManleySE, CullCA, HaddenD, TurnerRC, HolmanRR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321:405–412.
8.
OngKL, CheungBM, WongLY, WatNM, LamKS. Prevalence, treatment and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol, 2008; 18:222–229.
9.
HirschIB, O'BrienKD. How to best manage glycemia, non-glycemia during the time of acute myocardial infarction. Diabetes Technol Ther, 2012; 14,Suppl 1:S-22–S-32.
10.
NathanDM, ClearyPA, BacklundJY, GenuthSM, LachinJM, OrchardTJ, RaskinP, ZinmanB. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005; 353:2643–2653.
11.
Action to Control Cardiovascular Risk in Diabetes Study Group. GersteinHC, MillerME, ByingtonRP, GoffDCJr, BiggerJT, BuseJB, CushmanWC, GenuthS, Ismail-BeigiF, GrimmRHJr, ProbstfieldJL, Simons-MortonDG, FriedewaldWT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358:2545–2559.
ADVANCE Collaborative Group. PatelA, MacMahonS, ChalmersJ, NealB, BillotL, WoodwardM, MarreM, CooperM, GlasziouP, GrobbeeD, HametP, HarrapS, HellerS, LiuL, ManciaG, MogensenCE, PanC, PoulterN, RodgersA, WilliamsB, BompointS, de GalanBE, JoshiR, TravertF. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008; 358:2560–2572.
14.
DuckworthW, AbrairaC, MoritzT, RedaD, EmanueleN, ReavenPD, ZieveFJ, MarksJ, DavisSN, HaywardR, WarrenSR, GoldmanS, McCarrenM, VitekME, HendersonWG, HuangGD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009; 360:129–139.
15.
LemkesBA, NieuwdorpM, HoekstraJBL, HollemanF. The glycocalyx and cardiovascular disease in diabetes: should we judge the endothelium by its cover?Diabetes Technol Ther, 2012; 14,Suppl 1:S-3–S-10.
TruongUT, MaahsDM, DanielsSR. Cardiovascular disease in children and adolescents with diabetes: where are we, and where are we going?Diabetes Technol Ther, 2012; 14,Suppl 1:S-11–S-21.
